Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
- Disease/Condition
- Chronic Hepatitis C
- Drug/Device/Intervention
- Interferon
- Study type
- Observational
- Intervention type
- drug
- Primary sponsor
- Beijing Ditan Hospital
- Location
- Beijing, China
- Phase
- N/A
- Start date
- Aug 01, 2019
- End date
- Aug 01, 2020
- Enrollment
- 1000 participants
The incidence of liver cancer,The incidence of decompensated cirrhosis
This study was a clinical observational cohort study of two-way, non-intervention long-term
 dynamic follow-up. Enrolled in the Department of Liver Diseases, Beijing Ditan Hospital,
 Capital Medical University, with interferon combined with ribavirin (PR) antiviral therapy
 (PR treatment greater than or equal to 6 months) and/or direct acting antivirals (DAAs) In
 patients with chronic hepatitis C, the baseline, antiviral treatment and withdrawal follow-up
 data before the antiviral treatment were collected, and the patients were followed up for 3-6
 months. Clinical data such as clinical biochemistry, HCV RNA and serological markers
 (anti-HCV), AFP and liver imaging (liver ultrasound) were collected during the study period.
 At least 144 weeks of observation on the virological response and clinical outcome of
 anti-viral treatment of chronic hepatitis C, the main evaluation index of liver cancer and
 decompensated liver cirrhosis after stopping the drug, and exploring the antiviral treatment
 of patients Long-term virological response and clinical outcomes, clarifying their
 influencing factors.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04071353
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT04071353 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing Ditan Hospital and is currently status unknown. The study focuses on Chronic Hepatitis C. Target enrollment is 1000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.